Immunomodulatory effects of fetal and adult mesenchymal stem cells

Cytotherapy

Volumn 5, Issue 6, 2003, Pages 485-489

  Le Blanc, Katrina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; HLA ANTIGEN; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; PROTEIN A;

ADULT; ALLOIMMUNITY; ANIMAL CELL; BABOON; BONE MARROW; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FETUS; FETUS LIVER; GRAFT REJECTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MESENCHYME CELL; NATURAL KILLER CELL; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE INJURY; TISSUE REPAIR;

EID: 0347600715     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310003611     Document Type: Article

References (32)

1. Friedenstein AJ, Petrakova KV, Kuroksova AI et al. Heterotopic transplants of bone marrow: Analysis of precursor cells for osteogenic and hematopoietic tissue. Transplantation 1968;6:230-47.
2. Haynesworth SE, Goshima J, Goldberg VM et al. Characterization of cells with osteogenic potential from human marrow. Bone 1992;13:81-8.
3. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
4. Pittenger MF, Mackay AM, Beck SC et al. Multi-lineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
5. Campagnoli C, Roberts IA, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396-402.
6. Götherström C, Ringdén O, Westgren M et al. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003;32:265-72.
7. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992;13:69-80.
8. Deans RJ, Moseley A-M. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000;28:875-84.
9. Majumdar MK, Thiede MA, Mosca JD et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSC) and stromal cells. J Cell Physiol 1998;176:186-92.
10. + cells in NOD/SCID mice. Exp Hematol 2002;30:870-8.
11. Angelopoulou M, Novelli E, Grove J et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 2003;31:413-20.
12. Pereira RF, Halford KW, O'Hara MD et al. Cultured adherent cells from marrow can serve as long-lasting precursors for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995;92:4857-61.
13. Liechty KW, MacKenzie TC, Shaaban AF et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282-6.
14. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into non-human primates. Blood 2003;101:2999-3001.
15. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-97.
16. Majumdar M, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesencymal stem cells. J Biomed Sci 2003;10:228-41.
17. Le Blanc K, Tammik L, Zetterberg E, Rosendahl K, Ringdén O. HLA-expression and immunologic properties of undifferentiated and differentiated mesenchymal stem cells. Exp Hematol In press.
18. Götherström C, Ringdén O, Tammik C et al. Immunological properties of human fetal mesenchymal stem cells. Am J Obst Gynecol 2003;31:890-6.
19. McIntosh K, Bartholomew A. Stromal cell modulation of the immune system. Graft 2000;3:324-8.
20. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 2002;99:3838-43.
21. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive antigen specific T-cells to their cognate peptide. Blood 2003:101:3722-9.
22. Wilson JL, Proud G, Forsythe J et al. Renal allograft rejection. Tubular epithelial cells present alloantigen in the presence of costimulatory CD28 antibody. Transplantation 1995;59:91-7.
23. Laning J, Deluca JE, Isaacs C et al. In vitro analysis of CD40-CD154 and CD28-CD80/86 interactions in the primary T-cell response to allogeneic 'nonprofessional' antigen presenting cells. Transplantation 2001;71:1467-74.
24. Bartholomew A, Patil S, Mackay A et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Therapy 2001;12:1527-91.
25. Devine SM, Bartholomew AM, Mahmud N et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001;29:244-55.
26. Gurevitch O, Prigozhina TB, Pugatsch T, Slavin S. Transplantation of allogeneic or xenogenic bone marrow within the donor stromal microenvironment. Transplantation 1999;68:1362-8.
27. Bingaman AV, Waitze SY, Alexander DZ et al. Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning. Transplantation 2000;69:2491-6.
28. Yin D, Ma L, Zeng H, Sheen J, Zhong AS. Allograft tolerance induced by intact active bone cotransplantation and anti-CD40L monoclonal antibody therapy. Transplantation 2000;74:345-54.
29. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-8.
30. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
31. Frassoni F, Labopin M, Bacigalupo A et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft-versus-host disease: A matched pair analysis. Bone Marrow Transplant 2002;29(Suppl 2):S2.
32. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes (CTL), but not activated CTL or natural killer (NK) cells. Transplantation 2003;76:1208-13.